基于Meta分析评价参松养心胶囊治疗室性期前收缩的药物经济学  

Pharmacoeconomics Evaluation of Shensong Yangxin Capsule in the Treatment of Ventricular Premature Beat Based on Meta-analysis

作　　者：马路遥 王美娜[1] 孙晓 黎明修 张翔宇 赵慧怡 任明[1] MA Luyao;WANG Meina;SUN Xiao;LI Mingxiu;ZHANG Xiangyu;ZHAO Huiyi;REN Ming(Baokang Hospital Affiliated to Tianjin University of Traditional Chinese Medicine,Tianjin 300110,China)

机构地区：[1]天津中医药大学附属保康医院,天津300110

出　　处：《中西医结合心脑血管病杂志》2022年第8期1352-1358,共7页Chinese Journal of Integrative Medicine on Cardio-Cerebrovascular Disease

基　　金：国家重点研发计划项目(No.2018YFC1707403);国家中医药管理局行业专项(No.201107006);教育部创新团队发展计划项目(No.IRT_16R54)。

摘　　要：目的系统评价参松养心胶囊治疗室性期前收缩的有效性、安全性和经济性。方法检索中国知网、万方、维普、PubMed和中国生物医学文献数据库中的参松养心胶囊治疗室性期前收缩的随机对照试验(RCT),检索时间为2000年1月—2020年5月,采用Review Manager 5.3软件进行Meta分析,结合成本-效果分析进行经济学评价。结果共纳入17项RCT,涉及1507例病人。Meta分析结果显示:参松养心胶囊联合美托洛尔临床总有效率优于单用美托洛尔[OR=1.32,95%CI(1.24,1.41),P<0.00001],参松养心胶囊临床总有效率优于美托洛尔[OR=3.37,95%CI(1.60,7.10),P=0.001],参松养心胶囊临床总有效率优于普罗帕酮[OR=3.00,95%CI(1.65,5.46),P=0.0003]。参松养心胶囊联合美托洛尔痊愈率优于美托洛尔[OR=2.29,95%CI(1.17,4.49),P=0.02]。参松养心胶囊联合美托洛尔心电图总有效率优于美托洛尔[OR=3.54,95%CI(1.75,7.15),P=0.0004];参松养心胶囊联合美托洛尔不良反应发生率低于美托洛尔[OR=0.27,95%CI(0.14,0.52),P=0.0001];参松养心胶囊不良反应发生率低于普罗帕酮[OR=0.07,95%CI(0.02,0.22),P<0.00001]。药物经济学结果显示:参松养心胶囊治疗室性期前收缩具有成本效果优势,单因素敏感度分析证实了结果的稳定性。结论现有证据表明:参松养心胶囊治疗室性期前收缩有较好的有效性、安全性和经济性。Objective To systematically evaluate efficacy,safety and economy of Shensong Yangxin Capsule in the treatment of ventricular premature beat.Methods CNKI,WanFang,VIP,PubMed,and Chinese Bio Medical Literature Database were searched to collect randomized controlled trials(RCTs)of Shensong Yangxin Capsule in the treatment of ventricular premature beat from January 2000 to May 2020.Review Manager 5.3 software was used for Meta-analysis,and the economic evaluation was conducted based on the cost-effectiveness analysis.Results A total of 17 literatures were included,involving 1507 patients.The results of Meta-analysis showed that Shensong Yangxin Capsule combined with metoprolol possessed better clinical efficacy than that of metoprolol[OR=1.32,95%CI(1.24,1.41),P<0.00001],Shensong Yangxin Capsule possessed better clinical efficacy than that of metoprolol[OR=3.37,95%CI(1.60,7.10),P=0.001],Shensong Yangxin Capsule possessed better effect clinical efficacy than that of propafenone[OR=3.00,95%CI(1.65,5.46),P=0.0003],Shensong Yangxin Capsule combined with metoprolol possessed a higher recovery rate than that of metoprolol[OR=2.29,95%CI(1.17,4.49),P=0.02].Shensong Yangxin Capsule combined with metoprolol possessed better electrocardiogram effect than that of metoprolol[OR=3.54,95%CI(1.75,7.15),P=0.0004],with a lower incidence of adverse reactions than that of metoprolol[OR=0.27,95%CI(0.14,0.52),P=0.0001],and a lower incidence of adverse reactions than that of propafenone[OR=0.07,95%CI(0.02,0.22),P<0.00001].Pharmacoeconomics showed that Shensong Yangxin Capsule possessed cost effect advantage in the treatment of premature ventricular contraction.Univariate sensitivity analysis confirmed the stability of the results.Conclusion Current evidence showed that Shensong Yangxin Capsule had better efficacy,safety and economy in the treatment of ventricular premature beat.

关 键 词：室性期前收缩 参松养心胶囊 药物经济学 META分析 

分 类 号：R28[医药卫生—中药学]